key: cord-0332897-k8jpwxs1
authors: Almeda, A. F.; Grimes, S. M.; Lee, H.; Greer, S. U.; Shin, G.; McNamara, M.; Hooker, A. C.; Arce, M.; Kubit, M.; Schauer, M.; Van Hummelen, P.; Ma, C.; Mills, M.; Huang, R. J.; Hwang, J. H.; Amieva, M. R.; Han, S.; Ford, J. M.; Ji, H. P.
title: The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Stomach Malignancies
date: 2022-03-13
journal: nan
DOI: 10.1101/2022.03.10.22271914
sha: a638619918af382ef94ea2bcdba1fc33304e4bc4
doc_id: 332897
cord_uid: k8jpwxs1

Background: Gastric cancer (GC) is a leading cause of global cancer morbidity and mortality. Developing information systems which integrate clinical and genomic data may accelerate discoveries to improve cancer prevention, detection, and treatment. To support translational research in GC, we developed the GC Registry (GCR), a North American repository of clinical and cancer genomics data. Methods: GCR is a national registry with online self-enrollment. Entry criteria into the GCR included the following: (1) diagnosis of GC, (2) history of GC in a first- or second-degree family member or (3) known pathogenic or likely pathogenic germline mutation in the gene CDH1. Participants provided demographic and clinical information through a detailed (412-item) online survey. A subset of participants provided specimens of saliva and tumor samples. These tumor samples underwent exome sequencing, whole genome sequencing and transcriptome sequencing. Results: From 2011-2021, 567 individuals registered for the GCR and returned the clinical questionnaire. For this cohort 65% had a personal history of GC, 36% reported a family history of GC and 14% had a germline CDH1 mutation. Eighty-nine GC patients provided tumor tissue samples. For the initial pilot study, 41 tumors were sequenced using next generation sequencing. The data was analyzed for cancer mutations, copy number variations, gene expression, microbiome presence, neoantigens, immune infiltrates, and other features. We developed a searchable, web-based interface (the GCR Genome Explorer) to enable researchers access to these datasets. Conclusions: The GCR is a unique, North American GC registry which integrates both clinical and genomic annotation. Impact: Available for researchers through an open access, web-based explorer, we hope the GCR Genome Explorer accelerates collaborative GC research across the United States.

GCR included the following: (1) diagnosis of GC, (2) history of GC in a first-or second- neoantigens, immune infiltrates, and other features. We developed a searchable, web-20 based interface (the GCR Genome Explorer) to enable researchers access to these 21 datasets.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Conclusions: The GCR is a unique, North American GC registry which integrates both 1 clinical and genomic annotation. 5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 INTRODUCTION 1 Gastric cancer (GC) is a leading cause of cancer morbidity and mortality worldwide. 1 2 While incidence is lower in the United States, GC remains a major public health concern 3 with an estimated 116,000 prevalent cases nationwide in 2017. 2 GC is diagnosed at 4 generally advanced stages in the United States, where curative resection is often no 5 longer possible. 2,3 These data underscore the need for additional translational research 6 in GC etiology, prevention, early detection, and therapy. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 To address this knowledge gap, we established the Gastric Cancer Registry (GCR) in 1 2011. The goal of this project is to integrate granular patient clinical data (collected 2 through a detailed, 412-item online questionnaire) with comprehensive genomic 3 characterization of tumor samples. This includes gene expression, somatic mutations, 4 copy number variation, human leukocyte antigen genotypes, neoantigens, and intra-5 tumoral heterogeneity details. To facilitate public access to these data, we created the 6 GCR Genome Explorer (https://gcregistry-explorer.stanford.edu/), a browser-based 7 interactive tool which allows for querying of clinical and molecular annotation from the 8 GCR. In this manuscript, we describe the overall study design, methods for sample 9 collection and data generation, and characteristics of enrolled participants in the GCR 10 over a ten-year period (2011) (2012) (2013) (2014) (2015) (2016) (2017) (2018) (2019) (2020) (2021) . We also review features of the GCR Genome 11 Explorer and describe how this tool can be used by cancer researchers for translational 12 research.

Study design 16 Approval was obtained from the Stanford University Institutional Review Board (IRB-17 20285). The study was performed in accordance with the ethical standards delineated 18 in the 1964 Declaration of Helsinki and its later amendments. Eligible participants were 19 over 18 years of age and fulfilled one or more of the following criteria: personal history 20 of histologically proven GC, a family history of GC in a first-or second-degree relative, 21 and/or a known pathogenic or likely pathogenic mutation in the gene CDH1, also known 22 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 as Cadherin-1. From 2011-2014, only individuals with a GC diagnosis were included in 1 the study. Family history and a known germline CDH1 mutation were added as 2 eligibility criteria in 2014. Biospecimens were collected from residents of the United 3 States. Recruitment and enrollment for the GCR was conducted through referral by 4 local clinicians, local and regional pamphlet distribution at conferences and 5 interest/advocacy group events, social media advertisement and a study website 6 (https://gcregistry.stanford.edu/). Registrants use the website to complete the 7 questionnaire. Study data were collected and managed using REDCap electronic data capture tools 10 hosted at Stanford University. REDCap is a secure, web-based software platform 11 designed to support data capture for research studies, providing 1) an intuitive interface 12 for validated data capture; 2) audit trails for tracking data manipulation and export The questionnaire contained questions regarding subjects' demographics, medical 21 history, familial cancer history, and lifestyle behaviors. For providing updates in 22 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 personal or family history, participants could provide additional information using a 1 unique return code. Participants had the option of authorizing the release of medical 2 records related to the diagnosis and treatment of the patient's GC. This information 3 included treatment summaries from any chemotherapy or radiation therapy, the 4 operative notes from any surgeries and any pathology reports relating to the diagnosis 5 of GC. acids was determined through quantitation, genomic sizing, and fragmentation analysis. 21 We used an ultrasonicator to shear genomic DNA to a desired length of 300 base pairs.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) adapters. An amount of genomic DNA library was set aside for exome enrichment 3 using xGen Lockdown Probes and reagents (Integrated DNA Technologies, catalog no. The portal is a two-tier client-server application written using Ruby on Rails version 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. in the study, all participants were required to identify their eligibility status on the 12 enrollment questionnaire. The majority reported a personal history of GC. Some 13 participants met multiple eligibility criteria (e.g., having GC and a family history of GC).

14 Eligibility status with respect to sex, age, race, and ethnicity is depicted in Table 1 . 15 Participants were predominantly female (63%), White (76%), and non-Hispanic (53%).

The median age of all participants was 51 years (range: 18-92 years). The median age 17 of participants with GC was 68 years. Some participants did not report their sex, race, 18 ethnicity, or other demographic details as these questions were optional on the 19 enrollment survey. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10. 1101 /2022 The participants' commonly reported medications included non-steroidal anti-1 inflammatories, proton pump inhibitors and multivitamins. Common comorbidities 2 included high blood pressure, high cholesterol, and other cancers. Nearly a quarter of 3 participants with GC reported a history of gastric ulcers, gastroesophageal reflux 4 disease, or gastric polyps. Helicobacter pylori infection was reported by 16% of all 5 participants, and 20% of all participants with GC. Notably, a high proportion of 6 participants (65%) did not report or did not know their H. pylori status. where Lauren's classification was reported (N=24), the majority were diffuse-type 16 cancers (N=16). The tumors were generally aggressive and poorly differentiated (59%).

The majority of tumors were from patients with metastatic disease (54%). With respect 18 to anatomic location, 10% of tumors arose from the cardia, 73% arose from the non-19 cardia stomach, and 17% arose from an unreported location. The GCR Genome Explorer and pilot data release 22 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Public access is to the GCR Genome Explorer is available upon registration via the 1 following URL: https://gcregistry-explorer.stanford.edu/users/sign_in. At time of 2 publication, the Genome Explorer contains data from the initial 41 sequenced tumors 3 through the GCR. In addition, genomic data from 443 TCGA gastric cancers and 185 4 TCGA esophageal cancers are available through the GCR Genome Explorer for cross-5 reference. Future releases will incorporate data from additional GCR tumor samples. A There are several ways of accessing results through the GCR Genome Explorer.

Options include general summaries of the results as well as specific queries. All image 20 files and tables are available for download. On the home page (Figure 1) , the different 21 sample sets are displayed. For example, a user can query the GCR data set using the 22 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022.

"Explore Study" feature, which directs to a landing page with multiple tabs. In the 1 "Clinical Parameters" tab, the user will find visual and tabular representations of cohort 2 characteristics. The cohort can be queried with regards to sex, race, ethnicity, cancer 3 site, age at diagnosis, body mass index, smoking history, cancer diagnosis, Lauren 4 classification, and histologic differentiation. Under "Gene Summary," there are two 5 tables describing genes that are most frequently mutated or varied in copy number 6 within the GCR cohort. All cancer-associated genes are listed, along with genes 7 mutated in >10% of samples, or genes with copy number variation in >10% of samples.

The percentage filter will change across cohorts due to rounding, and due to gene 9 ranking ties (i.e., multiple genes being mutated across the same total number of 10 samples). The tables include the gene name, cytoband, number of samples displaying 11 the mutation or copy number variation and ranked order of genes based on the 12 percentage of samples affected. In addition, we provide annotations for genes that are CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 The tab "HLA Types" contains an overview and breakdown of specific HLA alleles for 20 1 patients in the GCR study. There are options to view the prevalence of specific HLA-A, 2 HLA-B, and HLA-C types within the study and within individual patients. In the next tab, For more discrete summaries, users can employ the "Gene" query function to view data 11 for a specific gene. We cite an example using the CDH1 tumor suppressor gene.

When searching all studies for CDH1 gene information, the user will find discrete 13 percentages and counts on its mutations, copy number variations, expression levels, The "Neoantigen" query gives the user the option to select an HLA allele type and view 21 a list of the candidate neoantigens. For example, the most prevalent HLA-A type in the 22 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 GCR-STCA study is A*02:01 (18.9%). Selecting this HLA type in the Neoantigen query 1 produces a breakdown of all neoantigen candidates. They are described by their gene, 2 chromosomal location, amino acid change and binding strength/rank based on their 3 predicted properties in terms of MHC1 interaction (Figure 3) . Like the "Gene" query, 4 the "Neoantigen" query function allows users to search data across multiple patient 5 cohorts. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22271914 doi: medRxiv preprint

The GCR's goal is to catalyze research which will accelerate the prevention, detection, 2 and treatment of this malignancy. Patients with GC, a family history of GC in a first-or 3 second-degree relative, a germline CDH1 mutation, or a combination of the three were 4 invited to enroll. Recruitment efforts were facilitated by making enrollment simple and 5 available to individuals who fulfill the eligibility criteria. Our national enrollment to 6 patients outside of the northern California region has enabled us to increase the 7 diversity of the participants. Through ongoing collaborations with other research groups 8 and healthcare centers across the globe, we are continuing to build out a robust 9 repository of clinical datasets, biospecimens and genomic data. The ongoing expansion 10 of the GCR will provide an even more diverse cohort and broaden the utility of this data 11 for research. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 While the pilot release of the Genome Explorer currently contains genomic data for 41 1 gastric tumors, our most recent enrollment will quadruple the number of samples 2 available for genomic studies. This influx of new participants is providing additional 3 clinical datasets such as pathology reports and other clinical metrics. On this expanded 4 cohort we are conducting additional genomic studies which will greatly increase the 5 overall number of tumors with genomic data. As the registry continues to accrue 6 participants and tumor samples, we anticipate that there will be improved statistical 7 power for future studies. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 patients from the United States, a region with a lower prevalence of H. pylori-induced 1 cancer. 28 2 3 For this iteration of the GCR's current registry we noted several limitations related to 4 patient reporting. First, participants in the GCR completed varying degrees of their 5 questionnaires. All participants who completed our online consent form were included 6 in the final cohort. However, some participants did not complete every field of their 7 questionnaire. Second, not all participants donated biological samples to the study. 8 Some patients elected not to contribute. This issue was exacerbated by the COVID-19 9 pandemic during which many patients were unable to donate saliva samples given the 10 biohazard issues. Third, using an online self-enrollment method limits participation to 11 individuals with access to the internet. One study suggested that older individuals and 12 those with lower self-rated internet ability are less likely to complete online enrollment 13 processes. 29 Finally, our ongoing recruitment is expanding the overall diversity of the 14 cohort. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Primary data is available on the Gastric Genome Explorer website (https://gcregistry-3 explorer.stanford.edu/). Other data generated in this study are available within the 4 article and its supplementary data files.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

Race/Ethnicity Ethnicity . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22271914 doi: medRxiv preprint Figure 2 . The GCR Genome-Explorer output of a "Gene" query across all study 1 cohorts for CDH1. The "Summary" page displays counts and percentages of samples 2 with CDH1 mutations, copy number variations, and expression levels. The "Mutation," 3 "Copy Number," "Expression," and "Neoantigen" tabs contain more detailed gene 4 alterations among the studies' patients. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22271914 doi: medRxiv preprint Figure 3 . Example of the "Neoantigen" query for HLA type A*02:01 within the GCR-1 STCA cohort. The table describes specific gene mutations that lead to the production of 2 a neoantigen and the predicted binding strength of the neoantigen to HLA allele 3 A*02:01. 4 5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22271914 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Global cancer 2 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 3 185 countries

SEER Cancer Statistics Review

Surveillance Research Program NCI. SEER*Explorer: An interactive website for SEER 9 cancer statistics

Diagnosis and Management of 12 Gastric Intestinal Metaplasia: Current Status and Future Directions. Gut Liver

Spanning the genomics era: the vital role of a single institution 15 biorepository for childhood cancer research over a decade. Translational pediatrics

Developing an institutional cancer biorepository for personalized medicine

The eMERGE Network: a consortium of 21 biorepositories linked to electronic medical records data for conducting genomic studies. BMC 22 medical genomics

Research electronic 24 data capture (REDCap)--a metadata-driven methodology and workflow process for providing 25 translational research informatics support

Whole genome analysis identifies the 31 association of TP53 genomic deletions with lower survival in Stage III colorectal cancer. 32 Scientific

xCell: digitally portraying the tissue cellular heterogeneity 39 landscape

Neo-antigens predicted by tumor genome meta-43 analysis correlate with increased patient survival

Exomics and 46 immunogenics: Bridging mutational load and immune checkpoints efficacy

Genomic Correlates of Immune-Cell Infiltrates in 1

The stomach cancer pooling (StoP) project: study 4 design and presentation

Alcohol consumption and gastric cancer risk-A 7 pooled analysis within the StoP project consortium

Cigarette smoking and gastric cancer in the Stomach 10 Cancer Pooling (StoP) Project

Citrus fruit intake and gastric cancer: The 13 stomach cancer pooling (StoP) project consortium

Meat intake and risk of gastric cancer in the Stomach 16 cancer Pooling (StoP) project

Education and gastric cancer risk-An individual 18 participant data meta-analysis in the StoP project consortium

Smoking and Helicobacter pylori infection: an 21 individual participant pooled analysis (Stomach Cancer Pooling-StoP Project)

Sex differences in the prevalence of Helicobacter 24 pylori infection: an individual participant data pooled analysis (StoP Project)

Occupational exposures and odds of gastric 27 cancer: a StoP project consortium pooled analysis

DBGC: A Database of Human Gastric Cancer. PLoS 30 One

Prevalence of Helicobacter pylori Positive 32

Gastric Adenocarcinoma Is Low and Decreasing in a US Population

Barriers encountered during 35 enrollment in an internet-mediated randomized controlled trial